Osteosarcoma
MONDO:0009807A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.
Also known as: bone tissue neoplasm, osteogenic sarcoma, osteoid sarcoma, osteosarcoma, osteosarcoma (disease), osteosarcoma, malignant, sarcoma of osteoid
2925 clinical trials for this condition and its sub-types, 169 tagged with Osteosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Osteosarcoma
-
Localized osteosarcoma 13 trials
-
Bone osteosarcoma 8 trials
5 sub-types
- Conventional osteosarcoma 0 trials Sub-types →
- Metachronous osteosarcoma of the bone 0 trials
- Osteosarcoma arising in bone Paget disease 0 trials
- Peripheral osteosarcoma 0 trials Sub-types →
- Telangiectatic osteogenic sarcoma 0 trials
-
Pediatric osteosarcoma 8 trials
3 sub-types
- Childhood extraosseous osteosarcoma 0 trials
- Childhood intracortical osteosarcoma 0 trials
- Childhood parosteal osteosarcoma 0 trials
-
Extraosseous osteosarcoma 2 trials
7 sub-types
- Adult extraskeletal osteosarcoma 0 trials
- Breast extraskeletal osteosarcoma 0 trials
- Central nervous system extraskeletal osteosarcoma 0 trials
- Childhood extraosseous osteosarcoma 0 trials
- Kidney osteogenic sarcoma 0 trials
- Liver extraskeletal osteosarcoma 0 trials
- Mediastinal extraskeletal osteosarcoma 0 trials
-
Low grade central osteosarcoma 0 trials
-
Multifocal osteogenic sarcoma 0 trials
2 sub-types
Most studied deeper sub-types
-
Can a smart drug hunt down sarcoma cells without harming healthy ones?
Disease control Not yet recruitingThis trial tests SOT106, a cancer medicine designed to find and kill cells that carry a marker called LRRC15, which appears on some osteosarcoma and soft tissue sarcoma tumors. The study has two parts: the first finds safe dose levels, and the second compares two doses to see whi…
Phase 1/2 • Sponsor: SOTIO Biotech a.s. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat sarcomas
Disease control Not yet recruitingThis early-stage trial is testing a combination of specially engineered immune cells (CAR T cells) and a vaccine for people with sarcoma that has come back or spread. The goal is to see if the treatment is safe and can help shrink tumors. About 20 participants will receive the th…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat sarcomas
Disease control Not yet recruitingThis trial tests a 4th-generation safety-engineered CAR T cell therapy for people with relapsed or late-stage sarcomas, including osteosarcoma and Ewing sarcoma. Participants receive a single infusion of these immune cells designed to target and attack sarcoma cells. The study ai…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo aims to stall bone sarcoma in phase 2 trial
Disease control Not yet recruitingThis study tests whether combining two drugs, lenvatinib and everolimus, works better than everolimus alone for people with advanced bone sarcoma (osteosarcoma, Ewing sarcoma, or chondrosarcoma) that has progressed after standard treatment. About 94 adults aged 19 to 79 will be r…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kids with tough cancers: drug combo trial launches
Disease control Not yet recruitingThis study tests a combination of chemotherapy drugs (liposomal irinotecan, vincristine, and temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have returned or not responded to treatment. The goal is to see if this combination c…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Light therapy may shield kids with cancer from chemo mouth sores
Prevention Not yet recruitingThis study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…
Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Could kids with bone cancer go home sooner after chemo?
Symptom relief Not yet recruitingThis study looks at whether children, teens, and young adults with newly diagnosed osteosarcoma can safely leave the hospital when their methotrexate levels are slightly higher than usual after standard chemotherapy. The goal is to shorten hospital stays without increasing side e…
Phase 2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can a single psychedelic dose ease despair in advanced cancer?
Symptom relief Not yet recruitingResearchers are testing whether a single high dose of psilocybin, given alongside a structured talking therapy called PEARL, reduces depressive symptoms in adults with advanced cancer. The trial enrolls 46 people in Ontario with stage IV solid tumors, sarcoma, melanoma, endocrine…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New app guides young cancer survivors through life after treatment
Knowledge-focused Not yet recruitingThis study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC